276 related articles for article (PubMed ID: 26988419)
21. SMYD2 lysine methyltransferase regulates leukemia cell growth and regeneration after genotoxic stress.
Zipin-Roitman A; Aqaqe N; Yassin M; Biechonski S; Amar M; van Delft MF; Gan OI; McDermott SP; Buzina A; Ketela T; Shlush L; Xie S; Voisin V; Moffat J; Minden MD; Dick JE; Milyavsky M
Oncotarget; 2017 Mar; 8(10):16712-16727. PubMed ID: 28187429
[TBL] [Abstract][Full Text] [Related]
22. Proteomic analyses of the SMYD family interactomes identify HSP90 as a novel target for SMYD2.
Abu-Farha M; Lanouette S; Elisma F; Tremblay V; Butson J; Figeys D; Couture JF
J Mol Cell Biol; 2011 Oct; 3(5):301-8. PubMed ID: 22028380
[TBL] [Abstract][Full Text] [Related]
23. SMYD2 Drives Mesendodermal Differentiation of Human Embryonic Stem Cells Through Mediating the Transcriptional Activation of Key Mesendodermal Genes.
Bai HJ; Zhang P; Ma L; Liang H; Wei G; Yang HT
Stem Cells; 2019 Nov; 37(11):1401-1415. PubMed ID: 31348575
[TBL] [Abstract][Full Text] [Related]
24. The lysine methyltransferase SMYD2 methylates the kinase domain of type II receptor BMPR2 and stimulates bone morphogenetic protein signaling.
Gao S; Wang Z; Wang W; Hu X; Chen P; Li J; Feng X; Wong J; Du JX
J Biol Chem; 2017 Jul; 292(30):12702-12712. PubMed ID: 28588028
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) Is Associated with Tumor Progression and Poor Prognosis in Patients with Papillary Thyroid Carcinoma.
Xu W; Chen F; Fei X; Yang X; Lu X
Med Sci Monit; 2018 Oct; 24():7357-7365. PubMed ID: 30319138
[TBL] [Abstract][Full Text] [Related]
26. Dysregulation of AKT Pathway by SMYD2-Mediated Lysine Methylation on PTEN.
Nakakido M; Deng Z; Suzuki T; Dohmae N; Nakamura Y; Hamamoto R
Neoplasia; 2015 Apr; 17(4):367-73. PubMed ID: 25925379
[TBL] [Abstract][Full Text] [Related]
27. Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells.
Verma A; Guha S; Wang H; Fok JY; Koul D; Abbruzzese J; Mehta K
Clin Cancer Res; 2008 Apr; 14(7):1997-2005. PubMed ID: 18381937
[TBL] [Abstract][Full Text] [Related]
28. Structure of human lysine methyltransferase Smyd2 reveals insights into the substrate divergence in Smyd proteins.
Xu S; Zhong C; Zhang T; Ding J
J Mol Cell Biol; 2011 Oct; 3(5):293-300. PubMed ID: 21724641
[TBL] [Abstract][Full Text] [Related]
29. The hepatitis B virus X protein promotes pancreatic cancer through modulation of the PI3K/AKT signaling pathway.
Chen Y; Bai X; Zhang Q; Wen L; Su W; Fu Q; Sun X; Lou Y; Yang J; Zhang J; Chen Q; Wang J; Liang T
Cancer Lett; 2016 Sep; 380(1):98-105. PubMed ID: 27339327
[TBL] [Abstract][Full Text] [Related]
30. Biochemical characterization of human SET and MYND domain-containing protein 2 methyltransferase.
Wu J; Cheung T; Grande C; Ferguson AD; Zhu X; Theriault K; Code E; Birr C; Keen N; Chen H
Biochemistry; 2011 Jul; 50(29):6488-97. PubMed ID: 21678921
[TBL] [Abstract][Full Text] [Related]
31. Quantitative Profiling of the Activity of Protein Lysine Methyltransferase SMYD2 Using SILAC-Based Proteomics.
Olsen JB; Cao XJ; Han B; Chen LH; Horvath A; Richardson TI; Campbell RM; Garcia BA; Nguyen H
Mol Cell Proteomics; 2016 Mar; 15(3):892-905. PubMed ID: 26750096
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic regulation of SMAD3 by histone methyltransferase SMYD2 promotes lung cancer metastasis.
Kim K; Ryu TY; Jung E; Han TS; Lee J; Kim SK; Roh YN; Lee MS; Jung CR; Lim JH; Hamamoto R; Lee HW; Hur K; Son MY; Kim DS; Cho HS
Exp Mol Med; 2023 May; 55(5):952-964. PubMed ID: 37121971
[TBL] [Abstract][Full Text] [Related]
33. Conformational Dynamics of Lysine Methyltransferase Smyd2. Insights into the Different Substrate Crevice Characteristics of Smyd2 and Smyd3.
Chandramouli B; Chillemi G
J Chem Inf Model; 2016 Dec; 56(12):2467-2475. PubMed ID: 27959541
[TBL] [Abstract][Full Text] [Related]
34. SMYD2 targets RIPK1 and restricts TNF-induced apoptosis and necroptosis to support colon tumor growth.
Yu YQ; Thonn V; Patankar JV; Thoma OM; Waldner M; Zielinska M; Bao LL; Gonzalez-Acera M; Wallmüller S; Engel FB; Stürzl M; Neurath MF; Liebing E; Becker C
Cell Death Dis; 2022 Jan; 13(1):52. PubMed ID: 35022391
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of SMYD2 contributes to malignant outcome in gastric cancer.
Komatsu S; Ichikawa D; Hirajima S; Nagata H; Nishimura Y; Kawaguchi T; Miyamae M; Okajima W; Ohashi T; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Imoto I; Inazawa J; Otsuji E
Br J Cancer; 2015 Jan; 112(2):357-64. PubMed ID: 25321194
[TBL] [Abstract][Full Text] [Related]
36. Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation.
Thomenius MJ; Totman J; Harvey D; Mitchell LH; Riera TV; Cosmopoulos K; Grassian AR; Klaus C; Foley M; Admirand EA; Jahic H; Majer C; Wigle T; Jacques SL; Gureasko J; Brach D; Lingaraj T; West K; Smith S; Rioux N; Waters NJ; Tang C; Raimondi A; Munchhof M; Mills JE; Ribich S; Porter Scott M; Kuntz KW; Janzen WP; Moyer M; Smith JJ; Chesworth R; Copeland RA; Boriack-Sjodin PA
PLoS One; 2018; 13(6):e0197372. PubMed ID: 29856759
[TBL] [Abstract][Full Text] [Related]
37. Design, Synthesis, and Biological Activity of Substrate Competitive SMYD2 Inhibitors.
Cowen SD; Russell D; Dakin LA; Chen H; Larsen NA; Godin R; Throner S; Zheng X; Molina A; Wu J; Cheung T; Howard T; Garcia-Arenas R; Keen N; Pendleton CS; Pietenpol JA; Ferguson AD
J Med Chem; 2016 Dec; 59(24):11079-11097. PubMed ID: 28002961
[TBL] [Abstract][Full Text] [Related]
38. Repression of p53 activity by Smyd2-mediated methylation.
Huang J; Perez-Burgos L; Placek BJ; Sengupta R; Richter M; Dorsey JA; Kubicek S; Opravil S; Jenuwein T; Berger SL
Nature; 2006 Nov; 444(7119):629-32. PubMed ID: 17108971
[TBL] [Abstract][Full Text] [Related]
39. RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation.
Cho HS; Hayami S; Toyokawa G; Maejima K; Yamane Y; Suzuki T; Dohmae N; Kogure M; Kang D; Neal DE; Ponder BA; Yamaue H; Nakamura Y; Hamamoto R
Neoplasia; 2012 Jun; 14(6):476-86. PubMed ID: 22787429
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma.
Komatsu S; Imoto I; Tsuda H; Kozaki KI; Muramatsu T; Shimada Y; Aiko S; Yoshizumi Y; Ichikawa D; Otsuji E; Inazawa J
Carcinogenesis; 2009 Jul; 30(7):1139-46. PubMed ID: 19423649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
